We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of its lead therapeutic candidate efruxifermin (EFX) this week, a fibroblast growth factor 21 analog, designed to ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, designed to treat amyotrophic lateral sclerosis (ALS), after the FDA lifted its ...